Cargando…
Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review
BACKGROUND: Cyclin-dependent kinase (CDK) 4/6 inhibitors have revolutionized the treatment landscape of hormone receptor-positive (HR(+)), human epidermal growth factor receptor 2-negative (HER2(−)) metastatic breast cancer, with an impressive efficacy and safety profile. Cytopenia is the main adver...
Autores principales: | Sharaf, Baha', AlMasri, Rama, Abdel-Razeq, Nayef, Salama, Osama, Hamad, Ibrahim, Abunasser, Mahmoud, Abdel-Razeq, Hikmat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743357/ https://www.ncbi.nlm.nih.gov/pubmed/35023941 http://dx.doi.org/10.2147/CCID.S344867 |
Ejemplares similares
-
Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022) -
Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2022) -
Urinary bladder metastasis from primary breast cancer, a rare and challenging diagnosis. A case report and literature review
por: Abdel-Razeq, Rashid, et al.
Publicado: (2022) -
Complete and Durable Response to Tamoxifen and Ovarian Ablation in the Treatment of Metastatic Breast Cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021) -
Late presentation and suboptimal treatment of breast cancer among Syrian refugees: a retrospective study
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)